CSL Behring is committed to improving the quality of life for patients with rare and serious diseases. The company develops, manufactures and markets a range of products for the following therapy areas:
Products for the treatment of Congenital FXIII Deficiency, Congenital Fibrinogen Deficiency, Haemophilia, Rapid Warfarin Reversal and von Willebrand Disease.
Products for the treatment of Immune Deficiency Disorders and Haemolytic Disease of the Newborn
Products for the treatment of Hypovolaemic Shock, Perioperative Prophylaxis of Bleedings, Hereditary Angioedema and Acute Myocardial Infarction